Abstract
The CD4<sup>+</sup> T cells count quantitatively defines the pathogen ecology in pulmonary infections. A CD4<sup>+</sup> T cells count < 100 cells/μL represents a critical threshold for opportunistic infections and complex co-infections. These findings support the integration of CD4<sup>+</sup> T cells counting into the initial assessment framework for severe pneumonia to guide precise empirical therapy and diagnostic strategies.
Introduction
Severe pneumonia remains a significant global health challenge, characterized by high mortality rates and diagnostic complexities. Rapid and accurate identification of causative pathogens is essential for effective treatment, yet traditional diagnostic methods—such as sputum cultures and standard PCR—often suffer from low sensitivity or prolonged turnaround times.
While clinicians recognize that a patient's immune status influences pathogen susceptibility, "immunosuppression" is frequently treated as a binary variable based on clinical history (e.g., HIV status or organ transplantation). This approach overlooks the nuanced spectrum of immune dysfunction. This study investigates whether peripheral CD4+ T cell counts can serve as a quantitative predictor of the pathogen landscape in severe pneumonia, enabling a transition from broad-spectrum empirical treatment to targeted precision medicine.
Methodology
This retrospective cohort study analyzed 221 adult patients diagnosed with severe pneumonia at the First Hospital of Jilin University between January and December 2024.
Patient Stratification
Patients were stratified into four immunological tiers based on their peripheral CD4+ T cell counts:
- Severe Immunosuppression: <100 cells/µL
- Moderate Immunosuppression: 100–200 cells/µL
- Low-Normal Immunity: 200–500 cells/µL
- Immunocompetent: ≥500 cells/µL
Diagnostic Approach
The primary diagnostic tool employed was targeted Next-Generation Sequencing (tNGS) performed on Bronchoalveolar Lavage Fluid (BALF). Unlike metagenomic NGS (mNGS), which sequences all genetic material in a sample, tNGS targets a predefined panel of known pathogens. This approach offers high sensitivity and a faster turnaround time suitable for clinical decision-making. Pathogen identification was validated against the NCBI RefSeq database.
Results
The 100-Cell Threshold and Opportunistic Infections
The study identified a CD4+ count of <100 cells/µL as a critical threshold. Below this level, the prevalence of opportunistic infections increased dramatically. For instance, Pneumocystis jirovecii (PJP) was detected in 39.6% of the severe immunosuppression group, compared to only 11.5% in the immunocompetent group. Similarly, Cytomegalovirus (CMV) detection rates fell from 35.4% to 5.8% as immune function improved ($p < 0.05$).
Complexity of Co-infections
Declining immunity was associated with increased microbiological complexity. The median number of distinct pathogen species detected in the severe immunosuppression group was 4, significantly higher than the median of 2 observed in immunocompetent patients. This suggests that a compromised immune system permits a "polymicrobial free-for-all," complicating the clinical management of these patients.
Inflammatory Markers and the IL-6 Paradox
Interestingly, immunocompetent patients (Stratum 4) exhibited the highest levels of Interleukin-6 (IL-6), a key pro-inflammatory marker. This suggests that a robust immune system mounts a more vigorous inflammatory response, which may itself contribute to lung injury. Conversely, severely immunosuppressed patients may have a blunted inflammatory response, making traditional markers like IL-6 less reliable for assessing infection severity in this population.
Discussion and Future Directions
This study demonstrates that CD4+ T cell counts provide a valuable quantitative map of the pathogen landscape in severe pneumonia. By identifying specific risk thresholds, clinicians can better anticipate the likely causative agents, particularly opportunistic pathogens like PJP and CMV.
Limitations
The study has several limitations, including its retrospective, single-center design, which may limit the generalizability of the findings. Additionally, the use of tNGS means that novel or rare organisms not included in the predefined panel would not be detected.
Conclusion
Integrating CD4+ T cell counting into the standard initial assessment framework for severe pneumonia could significantly improve diagnostic and therapeutic strategies. Future prospective, multicenter trials are needed to determine if this stratified approach leads to improved survival rates by facilitating earlier and more accurate antimicrobial therapy.
Summary updated